Acerta Pharma BV clinical trials

Acquired by AstraZeneca, Feb 2, 2016 · source ↗

The registry lists 41 studies whose lead sponsor is Acerta Pharma BV. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 41 of 41. All AstraZeneca studies →

• A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLActive, not recruitingNCT02970318Phase 3

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02180711Phase 1/2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaActive, not recruitingNCT02180724Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT02477696Phase 3

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLActive, not recruitingNCT02475681Phase 3

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaActive, not recruitingNCT02213926Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT03328273Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCLActive, not recruitingNCT02717624Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic LeukemiaActive, not recruitingNCT02029443Phase 1/2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)Active, not recruitingNCT02586857Phase 1/2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyActive, not recruitingNCT02717611Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLCompletedNCT02296918Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesCompletedNCT02328014Phase 1/2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT02157324Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaCompletedNCT02112526Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult ParticipantsCompletedNCT05140096Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19TerminatedNCT04497948Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its MetaboliteCompletedNCT03968848Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196CompletedNCT04914936Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult ParticipantsCompletedNCT04905043Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy ParticipantsCompletedNCT04901923Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult ParticipantsCompletedNCT04898101Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With OmeprazoleCompletedNCT04876807Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult ParticipantsCompletedNCT04867980Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196CompletedNCT04867941Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell MalignanciesTerminatedNCT03205046Phase 1/2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca

• An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02211014Phase 1

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic CancerCompletedNCT02362048Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)CompletedNCT02537444Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02448303Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT02454179Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder CancerCompletedNCT02351739Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic CancerTerminatedNCT02570711Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background MethotrexateCompletedNCT02387762Phase 2

  Sponsor listed in the registry: Acerta Pharma BV · First submitted before Acerta Pharma BV became part of AstraZeneca

• A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT02735876Phase 3

  Sponsor listed in the registry: Acerta Pharma BV · First submitted after Acerta Pharma BV became part of AstraZeneca